trending Market Intelligence /marketintelligence/en/news-insights/trending/Tj6tkcYe1paHLH-7eehSzA2 content esgSubNav
In This List

AstraZeneca sells rights to cancer drug for $250M

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


AstraZeneca sells rights to cancer drug for $250M

TerSera Therapeutics LLC acquired the U.S. and Canadian rights to AstraZeneca PLC's cancer drug Zoladex for an up-front payment of $250 million and up to a further $70 million in milestone-related payments and royalties on the drug's sale.

The sale was first announced in February.

Zoladex is an injectable luteinizing hormone-releasing medicine for treating prostate cancer, breast cancer and certain benign gynecological disorders, and was first approved in the U.S. and Canada in 1989.